Compare Merck & Co., Inc. (MRK) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Merck & Co., Inc. trades at $133.65 (market cap $321.77B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VCSH | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Fixed Income |
52-Week High | $131.84 | $80.20 |
52-Week Low | $77.60 | $78.41 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
VCSH trades at $78.615, up 0.16% with a bearish technical outlook as moving averages signal selling pressure while oscillators remain neutral. The ETF maintains a 4.77% yield with short 2.7-year duration, though recent analysis suggests limited upside due to tight credit spreads. Recent institutional activity shows mixed positioning with Apella Capital reducing holdings while Bessemer Group and Allspring increased stakes significantly.
The outlook remains cautious with downgrades to 'Hold' citing unattractive entry points, though the short duration provides downside protection. Key risks include credit spread widening and Fed policy uncertainty, while the primary opportunity lies in stable income generation for conservative investors seeking corporate bond exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
